The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Eastman Chemical's revenues will increase 30.5% and EPS will grow 67.6%.
The average estimate for revenue is $2.25 billion. On the bottom line, the average EPS estimate is $1.19.
Last quarter, Eastman Chemical tallied revenue of $2.26 billion. GAAP reported sales were 25% higher than the prior-year quarter's $1.81 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.57. GAAP EPS of $0.99 for Q3 were 19% lower than the prior-year quarter's $1.22 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 26.6%, 270 basis points better than the prior-year quarter. Operating margin was 17.6%, 200 basis points better than the prior-year quarter. Net margin was 6.8%, 280 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $8.18 billion. The average EPS estimate is $5.38.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 189 members out of 215 rating the stock outperform, and 26 members rating it underperform. Among 68 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 64 give Eastman Chemical a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Eastman Chemical is outperform, with an average price target of $60.57.
The rich are different than you and me: They might not notice the moneymaking stories right under our noses. In our new report, "Middle-Class Millionaire-Makers: 3 Stocks Wall Street's Too Rich to Notice," we give you three Peter Lynch-inspired buy-what-you-know stocks for the 99%. Click here for instant access to this free report.
- Add Eastman Chemical to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Eastman Chemical Is Becoming a Cash-Flow Machine
In five years, free cash flow has grown by nearly 500%. Management still has plenty of room left to boost shareholder value.
Eastman Chemical: With the Hedge Funds Out of the Way, Will Share Performance Improve?
Eastman Chemical has been treated roughly by hedge funds, and estimates for 2016 are very conservative. Its current valuation and yield suggest that this gloom is excessive.
Today's 3 Worst Stocks in the S&P 500
These three stocks stood out as some of the worst in the stock market today.